Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | CDK4 | P11802 | 6/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 2/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30929653 | 1.00 | LRRK2 (0.47) | LRRK2CDK2KCNH2CDK4CDK6 | |
| Hydrochloric Acid SCHEMBL633701 | 0.99 | LRRK2 (0.47) | LRRK2CDK2KCNH2CDK4CDK6 | |
| SCHEMBL633780 | 0.89 | CDK2 (0.41) | LRRK2CDK2KCNH2CDK4CDK6 | |
| SCHEMBL633781 | 0.89 | CDK2 (0.41) | LRRK2CDK2KCNH2CDK4CDK6 | |
| Hydrochloric Acid SCHEMBL634311 | 0.89 | CDK2 (0.40) | LRRK2CDK2KCNH2CDK4CDK6 | |
| Hydrochloric Acid SCHEMBL634312 | 0.89 | CDK2 (0.40) | LRRK2CDK2KCNH2CDK4CDK6 | |
| SCHEMBL633506 | 0.87 | KCNH2 (0.38) | LRRK2CDK2KCNH2CDK4CDK6 | |
| SCHEMBL633925 | 0.87 | KCNH2 (0.46) | LRRK2CDK2KCNH2CDK4CDK6 | |
| Hydrochloric Acid SCHEMBL634786 | 0.87 | KCNH2 (0.38) | LRRK2CDK2KCNH2CDK4CDK6 | |
| Hydrochloric Acid SCHEMBL633741 | 0.86 | KCNH2 (0.46) | LRRK2CDK2KCNH2CDK4CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178529-B2 | Imidazole substituted pyrimidines | ASTRAZENECA AB (SE) | 2012-05-15 | — | — | US | claimed |
| WO-2012050517-A1 | IMIDAZOLE SUBSTITUTED PYRIMIDINE HAVING A HIGH GSK3 INHIBITING POTENCY AS WELL AS PAN-KINASE SELECTIVITY | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | WO | claimed |
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | ASTRAZENECA AB (SE) | 2012-03-29 | — | — | US | claimed |
| EP-2419425-A1 | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE | AstraZeneca AB (SE) | 2012-02-22 | — | — | EP | claimed |
| WO-2010120237-A1 | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | WO | claimed |
| US-20100267723-A1 | Imidazole Substituted Pyrimidines | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | US | claimed |
| EP-4125911-B1 | OBICETRAPIB FOR TREATMENT OF DEMENTIAS | NEWAMSTERDAM PHARMA B V (NL) | 2024-04-24 | — | — | EP | disclosed |
| US-8178529-B2 | Imidazole substituted pyrimidines | ASTRAZENECA AB (SE) | 2012-05-15 | — | — | US | disclosed |
| US-8178529-B2 | Imidazole substituted pyrimidines | ASTRAZENECA AB (SE) | 2012-05-15 | — | — | US | disclosed |
| US-8178529-B2 | Imidazole substituted pyrimidines | ASTRAZENECA AB (SE) | 2012-05-15 | — | — | US | disclosed |
| WO-2012050517-A1 | IMIDAZOLE SUBSTITUTED PYRIMIDINE HAVING A HIGH GSK3 INHIBITING POTENCY AS WELL AS PAN-KINASE SELECTIVITY | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | WO | disclosed |
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | ASTRAZENECA AB (SE) | 2012-03-29 | — | — | US | disclosed |
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | ASTRAZENECA AB (SE) | 2012-03-29 | — | — | US | disclosed |
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | ASTRAZENECA AB (SE) | 2012-03-29 | — | — | US | disclosed |
| EP-2419425-A1 | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE | AstraZeneca AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120237-A1 | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010120237-A1 | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267723-A1 | Imidazole Substituted Pyrimidines | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267723-A1 | Imidazole Substituted Pyrimidines | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267723-A1 | Imidazole Substituted Pyrimidines | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077813-A1 | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease | GSK3A, GSK3B, PYGB | LRRK2 320/4885CDK2 239/4885KCNH2 2379/4885 |
| US-20100267723-A1 | Imidazole Substituted Pyrimidines | GSK3B, GSK3A, STK3 | LRRK2 122/4885CDK2 112/4885KCNH2 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.